TaiGen Biotechnology

TaiGen Biotechnology is a pharmaceutical R&D company based in Taipei, Taiwan, focused on innovative drug development to meet medical needs. Its pipeline includes the antibiotic Taijiexin (nemonoxacin), the influenza antiviral TG-1000 (Pixavir marboxil), the HIF-PHD inhibitor ISM-4808, the DPP1 inhibitor TG-4318, the health supplement Burixafor, and the hepatitis C drug Furaprevir. The company describes its business model as diversified and flexible, developing global market licensing from a Greater China operating platform toward international markets.

TaiGen Biotechnology is a pharmaceutical R&D company based in Taipei, Taiwan, focused on innovative drug development to meet medical needs. Its pipeline includes the antibiotic Taijiexin (nemonoxacin), the influenza antiviral TG-1000 (Pixavir marboxil), the HIF-PHD inhibitor ISM-4808, the DPP1 inhibitor TG-4318, the health supplement Burixafor, and the hepatitis C drug Furaprevir. The company describes its business model as diversified and flexible, developing global market licensing from a Greater China operating platform toward international markets. Its board of directors includes representatives from Gao Xiang Investment Co., Ltd., Yuen Foong Yu Investment Holding Co., Ltd., the National Development Fund of the Executive Yuan, and Taiwan Sugar Corporation.

R&D-driven, market-oriented pharmaceutical company dedicated to developing anti-infective drugs.

• Taijiexin (nemonoxacin)

  Antibiotic drug

• TG-1000 (Pixavir marboxil)

  Influenza antiviral drug

• ISM-4808

  HIF-PHD inhibitor

• TG-4318

  DPP1 inhibitor

• Burixafor

  Health supplement

• Furaprevir

  Hepatitis C drug

1. 1太景生物科技 - 專業開發抗感染藥物醫藥研發公司taigenbiotech.com
2. 2About-board-太景生物科技 - 專業開發抗感染藥物醫藥研發公司taigenbiotech.com
3. 3About-milestone-太景生物科技 - 專業開發抗感染藥物醫藥研發公司taigenbiotech.com
4. 4TaiGen Biotechnology (Taiwan)wikidata.org